Morgan Stanley
CUE icon

Morgan Stanley’s Cue Biopharma CUE Stock Holding History

Morgan Stanley’s Portfolio CUE Stock Details CUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4.22K Sell
612
-8
-1% -$75 ﹤0.01% 7187
2025
Q4 		$5.68K Sell
620
-297
-32% -$5.46K ﹤0.01% 7036
2025
Q3 		$19.8K Sell
917
-65
-7% -$1.52K ﹤0.01% 6691
2025
Q2 		$20.1K Buy
982
+26
+3% +$555 ﹤0.01% 6648
2025
Q1 		$26.1K Hold
956
– – ﹤0.01% 6471
2024
Q4 		$31.3K Sell
956
-167
-15% -$6.28K ﹤0.01% 6431
2024
Q3 		$25.5K Sell
1,123
-2,910
-72% -$63K ﹤0.01% 6430
2024
Q2 		$150K Sell
4,033
-963
-19% -$47.6K ﹤0.01% 5797
2024
Q1 		$283K Sell
4,996
-5,984
-54% -$422K ﹤0.01% 5592
2023
Q4 		$870K Buy
10,980
+6,829
+165% +$488K ﹤0.01% 5365
2023
Q3 		$286K Buy
4,151
+624
+18% +$60.9K ﹤0.01% 5423
2023
Q2 		$386K Buy
3,527
+229
+7% +$26.9K ﹤0.01% 5345
2023
Q1 		$353K Sell
3,298
-2,662
-45% -$254K ﹤0.01% 5452
2022
Q4 		$510K Sell
5,960
-2,550
-30% -$233K ﹤0.01% 5243
2022
Q3 		$569K Sell
8,510
-6,009
-41% -$517K ﹤0.01% 5202
2022
Q2 		$1.08M Buy
14,519
+7,900
+119% +$924K ﹤0.01% 4962
2022
Q1 		$969K Buy
6,619
+725
+12% +$154K ﹤0.01% 5018
2021
Q4 		$2M Sell
5,894
-9,914
-63% -$3.83M ﹤0.01% 4582
2021
Q3 		$6.91M Buy
15,808
+1,563
+11% +$545K ﹤0.01% 3339
2021
Q2 		$4.98M Buy
14,245
+3,608
+34% +$1.4M ﹤0.01% 3780
2021
Q1 		$3.89M Sell
10,637
-7,498
-41% -$3.09M ﹤0.01% 3675
2020
Q4 		$6.81M Buy
18,135
+10,099
+126% +$4.04M ﹤0.01% 2928
2020
Q3 		$3.63M Buy
8,036
+3,446
+75% +$1.99M ﹤0.01% 3035
2020
Q2 		$3.38M Buy
4,590
+3,283
+251% +$2.38M ﹤0.01% 3072
2020
Q1 		$556K Sell
1,307
-1,227
-48% -$595K ﹤0.01% 4317
2019
Q4 		$1.21M Buy
2,534
+1,583
+166% +$497K ﹤0.01% 4402
2019
Q3 		$240K Buy
951
+227
+31% +$54.5K ﹤0.01% 5043
2019
Q2 		$196K Buy
724
+24
+3% +$5.97K ﹤0.01% 5031
2019
Q1 		$162K Sell
700
-918
-57% -$175K ﹤0.01% 5172
2018
Q4 		$228K Sell
1,618
-1,049
-39% -$190K ﹤0.01% 5228
2018
Q3 		$725K Buy
2,667
+1,307
+96% +$378K ﹤0.01% 4763
2018
Q2 		$484K Buy
1,360
+583
+75% +$232K ﹤0.01% 5122
2018
Q1 		$327K Buy
+777
New +$354K ﹤0.01% 5236

Other funds holding CUE

BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
GWMR
GC Wealth Management RIA Cambridge, Massachusetts $1.73B AUM 16.14% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
LPC
Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
RSWM
Robertson Stephens Wealth Management San Francisco, California $4.06B AUM 32.22% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCBWMS
Texas Capital Bank Wealth Management Services Dallas, Texas $1.68B AUM 21.72% 1-Year Est. Return
AWM
Angeles Wealth Management Santa Monica, California $2.19B AUM 23.13% 1-Year Est. Return

Morgan Stanley's CUE Position: Q1 2026 in Review

Morgan Stanley reduced its Cue Biopharma (CUE) stake by 1.3% in Q1 2026, selling an estimated $75 and leaving 612 shares worth $4.22K. The position accounts for ﹤0.01% of the portfolio, ranked #7187.

Morgan Stanley first reported a position in CUE in Q1 2018 and has held it in 33 quarters since. The position peaked at $6.91M in Q3 2021. 55 funds tracked by Wall St. Rank hold CUE as of Q1 2026.

  • Morgan Stanley held 612 shares of Cue Biopharma worth $4.22K as of Q1 2026.
  • Morgan Stanley sold 8 Cue Biopharma shares in Q1 2026, an estimated $75.
  • Cue Biopharma made up ﹤0.01% of Morgan Stanley's portfolio in Q1 2026, its #7187 holding.
  • Morgan Stanley first reported a position in Cue Biopharma in Q1 2018 and has held it in 33 quarters since.
  • Morgan Stanley's Cue Biopharma position peaked at $6.91M in Q3 2021.
  • 55 funds tracked by Wall St. Rank held Cue Biopharma as of Q1 2026.

Based on Morgan Stanley's 13F filing for Q1 2026, filed 15 May 2026.